Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
DNLI
#1463
Denali Therapeutics Inc. - Common Stock
26.4
8
USD
+0.03%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+3.12%
Monthly Change
+21.13%
6 month change
+45.10%
Year Change
+63.76%
Previous Close
25.6
8
Open
26.4
8
Low
26.4
8
High
26.4
8
Volume
209
Markets
US Stock Market
Healthcare
Biotechnology
DNLI
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
120.98 M
122.83 M
136.68 M
139.16 M
145.22 M
158.59 M
158.71 M
Valuation ratios
Enterprise value
9.63 B
5.18 B
3.56 B
2.85 B
2.78 B
2.41 B
3.86 B
Price to earnings ratio
132.95
-18.66
-10.63
-20.18
-7.93
-5.56
-9.29
Price to sales ratio
28.12
111.38
31.98
8.89
—
—
—
Price to cash flow ratio
22.68
-25.64
14.17
8.21
9.64
-6.91
-11.46
Price to book ratio
8.2
5.63
3.33
2.85
2.73
2.81
1.21
Enterprise value to EBITDA ratio
135.11
-18.06
-10.77
-15.83
-5.64
-4.43
—
Profitability ratios
Return on assets %
0.04
-0.21
-0.22
-0.13
-0.31
-0.45
-0.1
Return on equity %
0.06
-0.3
-0.31
-0.14
-0.34
-0.51
-0.14
Return on invested capital %
156.99
-231.49
-210.75
-301.56
-650.72
-910.33
—
Gross margin %
100
100
100
100
—
—
—
Operating margin %
18.69
-607.78
-314.16
-59.51
—
—
—
EBITDA margin %
21.23
-590.12
-304.58
-54.45
—
—
—
Net margin %
21.19
-597.15
-300.56
-43.94
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
20.86
2.37
3.77
13.65
8.46
9.16
9.28
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.31
0.03
0.08
0.25
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
3.69
-1.74
-1.95
-2.61
-2.11
-2.39
-2.34
EBIT per share
0.56
-2.43
-2.71
-1.43
-3.05
-3.22
—
EBITDA per share
0.63
-2.36
-2.63
-1.31
-3
-3.15
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
13.04
7.12
10.64
7.53
5.06
5.03
5.29
Net current asset value per share
13.27
7.38
10.93
7.75
5.26
5.22
5.48
Tangible book value per share
10.21
7.92
8.3
7.5
7.48
5.87
4.96
Working capital per share
12.63
4.27
8.03
7.18
4.63
4.65
4.89
Book value per share
10.21
7.92
8.3
7.5
7.48
5.87
4.96
News
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
Denali to Sell Priority Review Voucher for $195M Cash Boost
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
Leqembi Isn’t Enough To Save Biogen Momentum (NASDAQ:BIIB)
Stocks Settle Higher on Iran Peace Hopes and Tech Strength
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers
Stocks Supported by US-Iran Peace Deal Optimism
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects